A potential species of next-generation probiotics? The dark and light sides of Bacteroides fragilis in health

Bacteroides fragilis (B. fragilis) is a commensal Gram-negative obligate anaerobe that resides in the mammalian lower gut and can profoundly affect the susceptibility of the host to inflammatory diseases. Previous studies have identified B. fragilis as a common opportunistic pathogen in clinical infections and suggested that it may be responsible for a range of diseases involving a permeable intestinal barrier. However, recent studies of the relationship between nontoxigenic B. fragilis and the immune system have indicated that several B. fragilis strains may be potential probiotic. In the present review, we summarize the factors influencing the intestinal abundance of B. fragilis and discuss the biological interactions between this microbe and the host. Immune system development, age, individual dietary habits, physical condition, drug intake and personal lifestyle habits can all affect the abundance of B. fragilis in the human intestine. Polysaccharide A or outer membrane vesicles from nontoxigenic B. fragilis may mediate beneficial interactions with the host, whereas enterotoxigenic B. fragilis toxin or lipopolysaccharide may stimulate colitis or even systemic inflammation. Generally, this review summarizes the biological characteristics of B. fragilis and describes future application of probiotics. [Display omitted] •Diet, drug, physical condition and lifestyle affect the abundance of B. fragilis.•Polysaccharide locus, T6SSs, BSAP and IgA influence colonization of B. fragilis.•PSA/OMVs/SCFAs NTBF exert beneficial immunomodulatory effects in the host.•BFT from ETBF may cause colitis/colorectal cancer and LPS may stimulate AD.